cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Endocrine Oncology Année : 2021

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

Laura Gerard
  • Fonction : Auteur
David Barthelemy
  • Fonction : Auteur
Arnaud Gauthier
  • Fonction : Auteur
Valerie Hervieu
  • Fonction : Auteur
Jonathan Lopez
  • Fonction : Auteur
Benjamin Gibert
  • Fonction : Auteur
Helene Lasolle
  • Fonction : Auteur
Laurence Chardon
  • Fonction : Auteur
Jessica Garcia
  • Fonction : Auteur
Gérald Raverot
  • Fonction : Auteur
Léa Payen

Résumé

Summary We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, FOLFIRINOX, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well correlated with the disease course, and cfDNA may be used as a predictive marker and/or as an early marker of response. In addition, the absolute count of atypical cells was elevated upon disease progression. Learning points cfDNA changes were well correlated with the Cushing’s syndrome course and with the tumour burden changes assessed by laboratory markers and by RECIST criteria. cfDNA analysis was used to determine the pharmacogenetic patterns of the present patient. An elevated number of atypical circulating cells was noticed upon disease progression.

Dates et versions

hal-04492472 , version 1 (06-03-2024)

Licence

Identifiants

Citer

Laura Gerard, David Barthelemy, Arnaud Gauthier, Valerie Hervieu, Jonathan Lopez, et al.. cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome. Endocrine Oncology, 2021, 1 (1), pp.K1-K6. ⟨10.1530/eo-21-0012⟩. ⟨hal-04492472⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More